ATXI.US Avenue Therapeutics Inc

Healthcare Pharmaceuticals USA Stocks
0.2800 USD
Close of Nov 13, 2026
0.1500 0.9570
Market cap
USD 922K
P/E
-
P/B
1.77x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ATXI.US undervalued?

Graham number

The Graham number of Avenue Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Avenue Therapeutics Inc fundamental analysis

No fundamental analysis for Avenue Therapeutics Inc yet.

Avenue Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Avenue Therapeutics Inc

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include ATX-04, a small molecule therapy for the treatment of Pompe disease; and intravenous tramadol, a schedule IV opioid to treat post-operative acute pain. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida.

Full company profile